Table 1.

Patient characteristics, by presence vs. absence of atrial fibrillation, in the Cleveland Clinic CKD Registry

Factor*	AF (N=6639)	No AF (N=55,820)	Overall (N=62,459)	p-value
Age	76.4±9.9	71.9±11.5	72.4±11.4	<0.001a
Male sex	54.4	42.6	43.8	<0.001c
African American	8.3	13.2	12.7	<0.001c
Smoking				<0.001c
No	91.3	77.3	78.8
Yes	4.3	7.4	7.0
Missing	4.4	15.3	14.2
BMI (kg/m2)	29.1±6.4	29.5±6.6	29.5±6.6	<0.001a
BMI categories				<0.001c
<18.5 kg/m2	1.6	1.3	1.3
18.5–24.9 kg/m2	24.3	22.3	22.5
25–29.9 kg/m2	35.5	34.0	34.1
30–34.9 kg/m2	21.0	21.3	21.3
35–39.9 kg/m2	9.0	9.8	9.7
>40 kg/m2	6.0	6.9	6.8
Missing	2.5	4.4	4.2
Diabetes	27.0	23.0	23.4	<0.001c
Malignancy	24.2	24.6	24.6	0.40c
Hypertension	92.8	84.0	84.9	<0.001c
Hyperlipidemia	82.4	77.1	77.7	<0.001c
Coronary artery disease	41.3	18.1	20.5	<0.001c
Congestive heart failure	28.7	5.4	7.9	<0.001c
Cerebrovascular disease	16.4	8.3	9.2	<0.001c
Peripheral vascular disease	4.8	3.0	3.2	<0.001c
Liver disease	5.0	5.5	5.5	0.081c
COPD/asthma	15.4	9.7	10.3	<0.001c
ACE-I /ARB	76.4	61.0	62.7	<0.001c
Diuretic	83.6	63.2	65.4	<0.001c
Statin	66.9	55.9	57.1	<0.001c
Beta Blocker use	86.1	51.4	55.1	<0.001c
Anticoagulant agents use	80.0	8.8	16.4	<0.001c
Antiplatelet agents use	18.8	14.3	14.7	<0.001c
eGFR, ml/min/1.73 m2	47.1±10.3	47.8±10.3	47.7±10.3	<0.001a
CKD Stage (eGFR range)				<0.001c
Stage 3a (45–59)	64.7	68.0	67.6
Stage 3b (30–44)	27.4	24.3	24.6
Stage 4 (15–29)	8.0	7.7	7.8
Albumin, g/dL	4.1±0.42	4.1±0.47	4.1±0.47	0.50a
Hemoglobin, mg/dL	12.8±1.8	12.8±1.8	12.8±1.8	0.049a
Proteinuria	25.4	25.5	25.5	0.85c
Insurance				<0.001c
Medicaid	0.17	0.35	0.33
Medicare	85.9	78.4	79.2
Missing	3.0	3.9	3.8
Other	11.0	17.3	16.6

^*Data shown as Mean+SD or column %

^at-test;

^cChi-square

BMI: Body Mass Index, COPD: Chronic Obstructive Pulmonary Disease, ACE-I: Angiotensin Converting Enzyme Inhibitor, ARB : Angiotensin II Receptor Blocker, eGFR: Estimated Glomerular Filtration Rate, CKD: Chronic Kidney Disease